Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jigsaw pty ltd - piperonyl butoxide; pyrethrins - aerosol - piperonyl butoxide benzodioxole active 60.0 g/kg; pyrethrins pyrethroid-pyrethrin active 14.0 g/kg - insecticide - agricultural/farm buildings | club | dairy or milking shed | domestic and/or public area | food preparation and/or storage area - ant | cockroach | earwig | flea | fly | mosquito | moth | silverfish | spider | adult | adult mosquitoes | argentine ant | ctenocephalides spp. | ground fleas | large cockroach | pharaoh ant | small cockroach

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

agnova technologies pty ltd - quintozene - dry flowable - quintozene benzene active 750.0 g/kg - fungicide - apple tree | bean | begonia | broccoli | bulbous iris | cabbage | calendula or marigold | carnation | cauliflower | chrysanthemu - base rot - sclerotium rolfsii | black rot | bottom rot or damping off of lettuce | brown patch | club root | collar rot - sclerotium rolfsii | common potato scab | crown rot - sclerotium rolfsii | damping off - rhizoctonia spp. | rhizoctonia soil fungus | root rot | soil-inhabiting fungus | stem rot - rhizoctonia solani | wirestem | fusarium spp. | helminthosporium spp. | rhizoctonia spp. | rhizoctonia stem rot | sclerotium base rot | soil fungi | southern blight | streptomyces scabies

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - clomifene citrate 50mg - tablet - 50 mg - active: clomifene citrate 50mg - clomiphene citrate is indicated for the treatment of ovulatory failure in patients desiring pregnancy, and whose husbands are fertile and potent. impediments to this goal must be excluded or adequately treated before beginning therapy. administration of clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction and in whom the following conditions apply: 1. normal liver function. 2. physiologic indications of normal endogenous oestrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary oestrogen, or from bleeding in response to progesterone). reduced oestrogen levels, while less favourable do not prevent successful therapy. 3. clomiphene citrate therapy is not effective for those patients with primary pituitary or ovarian failure. it cannot substitute for appropriate therapy of other disturbances leading to ovulatory dysfunction, e.g., diseases of the thyroid or adrenals. 4. particularly careful evaluation prior to clomiphene citrate therapy should be done in patients with abnormal uterine bleeding. it is most important that neoplastic lesions are detected.

Australia - English - Department of Health (Therapeutic Goods Administration)

icb medical distributors pty ltd - 31040 - orthosis, footwear, orthopaedic, shoe, - to be inserted into the user's footwear to correct and maintain the foot in its optimal postion in order to treat (or assist in conjunction with other therapies), various conditions such as; heel pain (plantar fasciitis), children's heel pain (sever's disease), heel spurs, achilles tendonitis, ball of foot pain (metatarsalgia), knee pain, osgood-schlatter's disease, lower back pain, bunions, shin splints, club foot & hip pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

thermo fisher scientific australia pty ltd -

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - azacitidine -

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - azacitidine, quantity: 100 mg - injection, powder for - excipient ingredients: mannitol - a)intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss), b)chronic myelomonocytic leukemia (cmmol 10%-29% marrow blasts without myeloproliferative disorder)), c) acute myeloid leukemia (aml) with 20-30% blasts and multi-lineage dysplasia, according to world health organisation classification (who). in whom allogenic stem cell transplantation is not indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; silicified microcrystalline cellulose; croscarmellose sodium; maize starch - apo-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, apo-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,apo-flecainide tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: magnesium stearate; maize starch; silicified microcrystalline cellulose; croscarmellose sodium - apo-flecainide is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, apo-flecainide should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,apo-flecainide tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - English - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate - flec-em is indicated for:,1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes b) due to dual av nodal pathways in patients with debilitating symptoms c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flec-em may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flec-em should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flec-em in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs. flec-em tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.